Related Experiment Video

Updated: Dec 28, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.6K

Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy

Rita De Santis1

  • 1Biotechnology Research and Development, Alfasigma SpA, Rome, Italy.

Mabs
|February 15, 2020
PubMed

Insights

Monoclonal antibodies targeting ErbB2 have become vital in cancer therapy, improving patient outcomes. This review examines current and future antibody-based treatments for ErbB2-positive cancers, considering medical needs and costs.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacoeconomics

Background:

  • Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) have significantly advanced cancer treatment over 30 years.
  • These therapies offer improved survival, progression-free survival, and quality of life compared to traditional chemotherapy.
  • ErbB2 is a key target in major cancers like breast and gastric, often resistant to chemotherapy.

Purpose of the Study:

  • To review approved and investigational anti-ErbB2 antibody therapeutics.
  • To analyze factors driving the development of next-generation anti-ErbB2 immunotherapies.
  • To consider unmet medical needs and pharmacoeconomic sustainability in future strategies.

Main Methods:

  • Literature review of approved original and biosimilar anti-ErbB2 products.
  • Analysis of investigational antibody-based therapeutics targeting ErbB2.
  • Examination of research and development drivers, including clinical and economic aspects.

Main Results:

  • ErbB2-targeted antibody therapies have a central role in treating various solid tumors.
  • Significant advancements have been made in developing novel anti-ErbB2 immunotherapeutics.
  • Pharmacoeconomic considerations are crucial for the sustainability of these advanced therapies.

Conclusions:

  • Anti-ErbB2 antibody therapies represent a major therapeutic advance in oncology.
  • Future development should address unmet needs and economic viability.
  • Strategic planning is essential for advancing next-generation ErbB2-targeted treatments.
Keywords:
ADCErbB2antibody drug conjugatesbiosimilarmonoclonal antibodysustainability

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

972

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
880
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K